Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 11 July 1986:
Vol. 233. no. 4760, pp. 209 - 212
DOI: 10.1126/science.3014647
Prev | Table of Contents | Next

Articles

Science, Vol 233, Issue 4760, 209-212
Copyright © 1986 by American Association for the Advancement of Science

articles

Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein

LA Lasky, JE Groopman, CW Fennie, PM Benz, DJ Capon, DJ Dowbenko, GR Nakamura, WM Nunes, ME Renz, and PW Berman

Mammalian cell lines have been engineered to produce a secreted form of the AIDS retrovirus envelope glycoprotein. The recombinant protein has been isolated from growth-conditioned culture media and used to immunize animals. Antibodies directed against the recombinant molecule were found to react with the envelope glycoprotein produced in virus-infected cells. Furthermore, these antibodies were able to directly inactivate the AIDS retrovirus in a neutralization assay in vitro. The expression system reported here should provide sufficient quantities of the AIDS retrovirus envelope protein for biological and vaccination studies.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles.
B.-Z. Wang, W. Liu, S.-M. Kang, M. Alam, C. Huang, L. Ye, Y. Sun, Y. Li, D. L. Kothe, P. Pushko, et al. (2007)
J. Virol. 81, 10869-10878
   Abstract »    Full Text »    PDF »
Expression and Characterization of a Soluble Form of Tomato Spotted Wilt Virus Glycoprotein GN.
A. E. Whitfield, D. E. Ullman, and T. L. German (2004)
J. Virol. 78, 13197-13206
   Abstract »    Full Text »    PDF »
Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo Efficacy of an Immunoconjugate.
S. Ross, S. D. Spencer, I. Holcomb, C. Tan, J. Hongo, B. Devaux, L. Rangell, G. A. Keller, P. Schow, R. M. Steeves, et al. (2002)
Cancer Res. 62, 2546-2553
   Abstract »    Full Text »    PDF »
Cellular Membrane-Binding Ability of the C-Terminal Cytoplasmic Domain of Human Immunodeficiency Virus Type 1 Envelope Transmembrane Protein gp41.
S. S.-L. Chen, S.-F. Lee, and C.-T. Wang (2001)
J. Virol. 75, 9925-9938
   Abstract »    Full Text »    PDF »
Cytokine-Stimulated, But Not HIV-Infected, Human Monocyte-Derived Macrophages Produce Neurotoxic Levels of L-Cysteine.
M. W. Yeh, M. Kaul, J. Zheng, H. S. L. M. Nottet, M. Thylin, H. E. Gendelman, and S. A. Lipton (2000)
J. Immunol. 164, 4265-4270
   Abstract »    Full Text »    PDF »
Baculovirus-based Genetic Screen for Antiapoptotic Genes Identifies a Novel IAP.
S. Seshagiri, D. Vucic, J. Lee, and V. M. Dixit (1999)
J. Biol. Chem. 274, 36769-36773
   Abstract »    Full Text »    PDF »
RIP3, a Novel Apoptosis-inducing Kinase.
X. Sun, J. Lee, T. Navas, D. T. Baldwin, T. A. Stewart, and V. M. Dixit (1999)
J. Biol. Chem. 274, 16871-16875
   Abstract »    Full Text »    PDF »
A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2.
G. Schaefer, R. W. Akita, and M. X. Sliwkowski (1999)
J. Biol. Chem. 274, 859-866
   Abstract »    Full Text »    PDF »
The next steps toward a global AIDS vaccine.
W. Koff (1994)
Science 266, 1335-1337
   PDF »
Galactose oxidation in the design of immunogenic vaccines.
B Zheng, S. Brett, J. Tite, M. Lifely, T. Brodie, and J Rhodes (1992)
Science 256, 1560-1563
   Abstract »    PDF »
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
K. Steimer, C. Scandella, P. Skiles, and N. Haigwood (1991)
Science 254, 105-108
   Abstract »    PDF »
Biological Agents in Infectious Diseases.
S. G. Louie and G. S. Jaresko (1991)
Journal of Pharmacy Practice 4, 326-341
   Abstract »    PDF »
HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists.
E. Dreyer, P. Kaiser, J. Offermann, and S. Lipton (1990)
Science 248, 364-367
   Abstract »    PDF »
HIV-infected cells are killed by rCD4-ricin A chain.
M. Till, V Ghetie, T Gregory, E. Patzer, J. Porter, J. Uhr, D. Capon, and E. Vitetta (1988)
Science 242, 1166-1168
   Abstract »    PDF »
Development and testing of AIDS vaccines.
W. Koff and D. Hoth (1988)
Science 241, 426-432
   Abstract »    PDF »
Type-restricted neutralization of molecular clones of human immunodeficiency virus.
D. Looney, A. Fisher, S. Putney, Rusche JR, R. Redfield, D. Burke, R. Gallo, and F Wong-Staal (1988)
Science 241, 357-359
   Abstract »    PDF »
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.
D. Smith, R. Byrn, S. Marsters, T Gregory, J. Groopman, and D. Capon (1987)
Science 238, 1704-1707
   Abstract »    PDF »
Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis.
D. Knight, F. Flomerfelt, and J Ghrayeb (1987)
Science 236, 837-840
   Abstract »    PDF »
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.
S. Putney, T. Matthews, W. Robey, D. Lynn, M Robert-Guroff, W. Mueller, A. Langlois, J Ghrayeb, S. Petteway Jr, K. Weinhold, et al. (1986)
Science 234, 1392-1395
   Abstract »    PDF »
Strategies for an AIDS vaccine.
D. Barnes (1986)
Science 233, 1149-1153
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)